Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. - Wikidata - wikimedia - TriplyDB

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33373887

about

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant Advances in the treatment of relapsed or refractory Hodgkin's lymphoma Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.Hodgkin's lymphoma therapy: past, present, and future.Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.Managing relapsed and refractory Hodgkin lymphoma.Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Current role of gemcitabine in the treatment of Hodgkin lymphoma.Optimal treatment for relapsing patients with Hodgkin lymphoma.Hodgkin's lymphoma: current treatment strategies and novel approaches.Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.The role of autologous transplantation in Hodgkin lymphoma.State of the art in the treatment of Hodgkin lymphoma.Advances in the treatment of Hodgkin lymphoma.Classical Hodgkin's lymphoma: past, present and future perspectives.Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.The new therapeutical scenario of Hodgkin lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Treatment of relapsed and refractory Hodgkin Lymphoma.A Review of Autologous Stem Cell Transplantation in Lymphoma.Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma.Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

P2860

Q24201885-850C1C67-5699-4AF4-BF10-3F37A90A1C0D Q27022992-6CF79B7E-5ECD-4857-8F24-4C0343AA8736 Q27694504-E38CD769-40AB-4793-9C2D-975481005483 Q33418817-322058BE-5489-4DE2-A303-C877F3DE70C7 Q33886267-4016472D-C9C0-4104-901E-B9FB3484FF3D Q34231085-0D0441BD-7E63-4CC7-81E2-979ED6BAB2B1 Q34296914-107B8243-48E8-4D6D-91ED-D4857272A789 Q34549230-39E0CADB-C8E9-4600-920A-D3DF840BA2DD Q34664223-440AB111-762C-4A6D-A848-8B40F14BE843 Q35705317-4F5A3001-3D03-49B7-B29C-1DB87DA93C2A Q35735986-C4D9DCFD-EC75-4AFD-9FCC-86DB1C4C3100 Q36094726-4561CC0E-1ADF-402B-B3AA-9D68F0F22D7A Q36135751-FA72FA1A-E0A8-4A44-9D31-5FD800C5178C Q37086162-ABC7A1CF-1720-4B30-A313-13472D2A5538 Q37146056-6DA2A71E-C8E0-4564-AD5D-61FA37C858B0 Q37152761-65BE520C-BF30-42AC-ACFD-C8F0BBB40437 Q37810094-D0E73FA6-D69B-4993-9820-00DBE9E1FC71 Q37810114-A43D5087-C191-47F8-A2FD-F44808027949 Q37816470-746D72C7-A452-4DF7-9C1D-438B1CC3E634 Q37832198-FE3AB726-1274-466B-8B63-7DED18FC6967 Q37874982-EA5D3DD4-520A-49D0-B383-0482E142135F Q38017914-B934AD3D-3D72-42C1-8C2A-DA897315ED5D Q38051197-636E742A-84C2-4890-BA8D-0B00BE0572DC Q38162057-062AB0E3-0F92-48F8-B370-22ABE6073344 Q38205880-C3C95B18-AC96-4A77-9CCB-ACA0F18BAA33 Q38513816-3F48D809-4C1D-4567-B0B3-30DF8BEC616F Q38664909-E085E658-EB16-4C74-B868-5F20B6F1B88D Q38920093-6B267703-A6C2-4657-8E0B-FB507C9EF3A2 Q39288544-64898C7D-7B70-4EE7-B9B4-044F4100CB0D Q39761923-E0CFD22A-87D3-42D2-933B-F5CD2390D3A7 Q40205866-A951AFFF-DA3F-44D4-887C-F1DF93FDC8C6 Q41029436-65FBEFF0-A2AD-4F26-B740-3155CDEEEB2B Q42375641-B15DA51B-5B1A-485C-8B02-3CA1D53DC036 Q44120728-83C31256-F688-456E-8914-E9348E3FBAF1 Q44312656-A209F341-BB63-4F9F-8A3B-0B94C77C9A0A Q44670113-DD3698AC-2AB7-4B3D-B05F-9CCF1775B083 Q46973779-D7C88964-2C9C-4B1A-AD5E-BF17981489D6 Q47562175-F92B0C2F-3966-4D5E-8742-C04C0D764B94 Q47563022-A1F0DF7D-441E-4807-85AF-6F05CEDEAC9E Q47852690-8334AFF3-ABA1-4D8D-8C19-5A09FF2BB567

P2860

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33373887

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Ifosfamide, gemcitabine, and v ...... d relapsed Hodgkin's lymphoma.

@ast

Ifosfamide, gemcitabine, and v ...... d relapsed Hodgkin's lymphoma.

@en

type

label

Ifosfamide, gemcitabine, and v ...... d relapsed Hodgkin's lymphoma.

@ast

Ifosfamide, gemcitabine, and v ...... d relapsed Hodgkin's lymphoma.

@en

prefLabel

Ifosfamide, gemcitabine, and v ...... d relapsed Hodgkin's lymphoma.

@ast

Ifosfamide, gemcitabine, and v ...... d relapsed Hodgkin's lymphoma.

@en

P1433

Q33373887-4427704D-B3B6-4A4A-AB2C-68CE1BBBC9D1

P1476

Q33373887-343F4C6F-B870-4D95-96C1-EB6779EDD5FF

P2093

Q33373887-1CEE7F03-6F95-4F8E-8A4D-328768AF713D

Q33373887-3916C077-2375-4EE0-B3CB-0CCC3F3227C6

Q33373887-4F34A385-389D-4EA4-9E3C-67690F6E5352

Q33373887-5E940987-2D7C-4E68-8416-DE699ABB8095

Q33373887-AC8AD491-0349-4495-A66C-E3F0387877CA

Q33373887-D8A3233E-003E-4826-95CB-00BA562B3A09

Q33373887-DCBF860B-768C-43FF-82C2-176725EBD1C3

Q33373887-DECA9093-79CF-4549-8701-52A27E554C2D

Q33373887-F0FC5D71-9778-4B0B-A830-1D5B4E1DD00C

Q33373887-F3E0766A-5408-4AF4-AC63-DB03438B84F9

P304

Q33373887-543B7AE9-5744-46F0-933B-97AEBA8127B8

P31

Q33373887-2371793E-3A71-4721-B1E1-A20B415E5CD0

P356

Q33373887-58103FE5-F6C9-4166-AAD2-AF66D3C38D1B

P433

Q33373887-0E22AC94-C43D-4982-83D6-541B87D61AD8

P478

Q33373887-88B6B8D6-F3DC-4DC4-9EFF-11D32A73C36D

P50

Q33373887-94502CC0-E1A4-46CC-B981-02893BC5A249

Q33373887-ED8115B5-12B1-41B6-92E8-4A301242FA28

P577

Q33373887-7029DA3B-2352-44A5-862C-FC6D5D2E6BF3

P5875

Q33373887-AA8636BF-645F-4CC4-BC7B-8DD335173434

P698

Q33373887-D6CC4486-FB7F-492C-B149-41C5143CD244

P356

P1433

P1476

Ifosfamide, gemcitabine, and v ...... d relapsed Hodgkin's lymphoma.

@en

P2093

Andrea Nozza

http://www.w3.org/2001/XMLSchema#string

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

Barbara Sarina

http://www.w3.org/2001/XMLSchema#string

Emanuela Morenghi

http://www.w3.org/2001/XMLSchema#string

Graziella Pinotti

http://www.w3.org/2001/XMLSchema#string

Licia Siracusano

http://www.w3.org/2001/XMLSchema#string

Mariagrazia Michieli

http://www.w3.org/2001/XMLSchema#string

Massimo Magagnoli

http://www.w3.org/2001/XMLSchema#string

Monica Balzarotti

http://www.w3.org/2001/XMLSchema#string

Umberto Tirelli

http://www.w3.org/2001/XMLSchema#string

P304

35-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.10661

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6572286

http://www.w3.org/2001/XMLSchema#string

P698

17229633

http://www.w3.org/2001/XMLSchema#string